Sara Robinson, MD
Hematology & Oncology · Longmont, CONPI 1124293535
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $194 of the $251 with a category attached, or 77.1%. 9 manufacturers reported payments, led by Myriad Genetic Laboratories, Inc. at 25.3% of the total. Reporting peaked in 2022 at $101 and has fallen 67.4% since, to $33 in 2023. That places this record below the midpoint for hematology & oncology clinicians in CO, where the typical reported total is $1,826.
Across 14 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$63
- Therapeuticsmd, Inc.$42
- Vifor Pharma, Inc.$40
- Myovant Sciences Inc.$24
- Merck$22
- Bayer$17
- plus $43 from 3 others
Across 587 payments — averaging $4818.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$911K
- Genentech, Inc.$876K
- Radius Health, Inc.$329K
- Hoffmann-la Roche Limited$246K
- Stemline Therapeutics Inc.$150K
- Gilead$126K
- plus $190K from 6 others
What the payments were for
- Food & beverage$19477%
- Education$5823%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 4 | $63 |
| Therapeuticsmd, Inc. | 2 | $42 |
| Vifor Pharma, Inc. | 1 | $40 |
| Myovant Sciences Inc. | 1 | $24 |
| Merck | 2 | $22 |
| Bayer | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Gilead | 1 | $12 |
How this compares
$251 in reported general payments places this provider in the 20th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 19 | $429,870 |
| Lenalidomide | 23 | $281,222 |
| VerzenioAbemaciclib | 11 | $163,201 |
| ImbruvicaIbrutinib | 12 | $123,616 |
| BrukinsaZanubrutinib | 12 | $45,433 |
| EliquisApixaban | 12 | $9,799 |
| Exemestane | 24 | $2,832 |
| Tamoxifen Citrate | 88 | $2,459 |
| Anastrozole | 170 | $1,967 |
| Letrozole | 80 | $1,841 |
| Imatinib Mesylate | 13 | $945 |
| Potassium Chloride | 13 | $641 |
| Dexamethasone | 42 | $625 |
| Gabapentin | 41 | $473 |
| Acyclovir | 20 | $323 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Longmont
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- John BurkeAurora$321K
- Manojkumar BupathiLittleton$312K
- Steven SchusterFort Collins$298K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Robert RifkinDenver$270K
- Christopher BentonEnglewood$249K
- Mabel MardonesDenver$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.